Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Fed Bioequivalence Study of CBZ Formulations

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02132897
Recruitment Status : Completed
First Posted : May 7, 2014
Last Update Posted : June 17, 2014
Sponsor:
Information provided by (Responsible Party):
Francisco E. Estevez-Carrizo, M.D., Center for Clinical Pharmacology Research Bdbeq S.A.

Brief Summary:

Controlled release Carbamazepine (CBZ) is a antiepileptic, antineuralgic and mood stabilizer drug. The CR formulation of CBZ is slowly absorbed and the elimination half life varies with time due to metabolism autoinduction.

The primary objective of this study is to estimate the bioequivalence of the new brand generic product (Auration(R) CR) 400 mg manufactured in Uruguay vs. the innovative product (Tegretol(R) CR) 400 mg manufactured in Brasil, under fed conditions. The secondary objective will be evaluation of safety issues.

The study design will be randomized two sequences, two periods and crossover. For a power of not less than 80% sample size was estimated to be 20 healthy male subjects. Products will be administered with food (high calories/high fat breakfast) after an overnight fast.

Time vs. concentration curves will be built for each subject and formulation and Area Under Curve (AUC0240) will be estimated using the trapezoid rule, the AUC 0-inf. (from time 0 to infinity) will be estimated using the formula Cz/Ke, Cmax will be taken from the individual curves.

This parameters will be statistically processed with the WinNonlin 6.3 Pharmacokinetics/Statistic software in order to prove bioequivalence between the study products.


Condition or disease Intervention/treatment Phase
Bio-equivalence Study Fed Conditions Drug: Auration CR Tablets 400 Single Dose-Tegretol CR 400 Single Dose Drug: Tegretol CR 400 Single Dose-Auration CR 400 Single Dose Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single (Investigator)
Official Title: Fed Bioequivalence Study of Carbamazepine Controlled Release Formulations in Healthy Male Uruguayan Subjects
Study Start Date : May 2014
Actual Primary Completion Date : June 2014
Actual Study Completion Date : June 2014

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
TR (Test - Reference)
Sequence : Auration CR 400 Single Dose/Tegretol CR 400 Single Dose
Drug: Auration CR Tablets 400 Single Dose-Tegretol CR 400 Single Dose
Carbamazepine CR Tablets 400 milligrams is given orally with 250 mL of water at room temperature.
Other Names:
  • Carbamazepine
  • Carbamazepine CR
  • Carbamazepine CR 400 millligrams

RT (Reference - Test)
Sequence: Tegretol CR 400 Single Dose/Auration CR 400 Single Dose
Drug: Tegretol CR 400 Single Dose-Auration CR 400 Single Dose
Auration CR 400 milligrams Single Dose is given orally with 250 mL of water at room temperature.
Other Names:
  • Carbamazepine
  • Carbamazepine CR
  • Carbamazepine CR 400




Primary Outcome Measures :
  1. AUC0-240 [ Time Frame: 10 days ]
    Area Under the CBZ Concentration vs. time curve from sample time point 0 hour to sample time point 240 hour.

  2. AUC0-inf [ Time Frame: 0 to 240 hours ]
    Area Under the CBZ Concentrations vs, time curve from sample time point 0 hour to sample time point 240 hours plus extrapolation to infinity of the terminal concentration slope.

  3. Cmax [ Time Frame: 12 to 48 hours ]
    The maximum concentration in the CBZ concentrations vs. time curves for each subject and each formulation.


Secondary Outcome Measures :
  1. AE [ Time Frame: 31 days ]
    Recording of all adverse events (AE) occurring during the study: expected, unexpected and serious (SAE) from tree different sources. The AEs may be clinical occurrences, abnormal labs or ECG alterations.


Other Outcome Measures:
  1. Tmax [ Time Frame: 12 to 48 hours ]
    Time from 0 concentration sample point to the Cmax sample point.

  2. Ke [ Time Frame: From 48 to 240 hours ]
    The constant rate of elimination (Ke) is the slope of the terminal phase of the CBZ concentration vs. time curve.

  3. T1/2e [ Time Frame: 48 to 240 hours ]
    It is the time that CBZ concentration, in the elimination (terminal) phase, fall off by half.

  4. Vital signs [ Time Frame: 20 days ]
    Measuring of blood pressure, heart rate, body temperature and ventilation rate.

  5. Admission and discharge screening [ Time Frame: 21 days ]
    Laboratory analysis and ECG performed prior to admission to the clinic and prior to discharge from the study.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Non-smoking or smokers of less than 5 cigarettes/day, within the age range of 18 to 50 years.
  • Body Mass Index (BMI = weight/height2) greater than or equal to 18.5 kg/m2 and less than or equal to 24.9 kg/m2.
  • No clinically significant findings in the physical examination, 12-lead electrocardiogram (ECG) and vital signs (blood pressure between 100-140/58-90 mmHg, heart rate between 50-99 beats/min, temperature between 35.8ºC and 37.6ºC, respiration rate between 12 and 20 breaths/minute)
  • No clinical laboratory values outside of the acceptable range as per protocol, unless the Principal Investigator or Sub-investigator decides that they are not clinically significant (NCS).
  • Availability of the subject for the entire study period and willingness of the subject to adhere to protocol requirements.
  • The subject agrees to abstain from alcohol, coffee and other food and drinks containing methylxanthines (mate, tea, cola, chocolate) for 48hours, and grapefruit containing food and beverages for 72 hours prior study drug administration and during each study period.

Exclusion Criteria:

  • Known history of hypersensitivity to Carbamazepine and/or related drugs.
  • Positive test for hepatitis B surface antigen, hepatitis C or HIV.
  • Known history of gastrointestinal (e.g: gastritis, inflammatory bowel disease, celiac disease), cardiac, pulmonary, endocrine, musculoskeletal, neurological, hematological, immunological, hepatic or renal disease, or malignancies, unless deemed NCS by the Principal Investigator or Sub-investigator.
  • Any history of peptic ulcer disease or gastrointestinal (GI) bleeding.
  • Any history of gastrointestinal surgery (except for appendectomy).
  • Presence of any significant physical or organ abnormality.
  • Any illness during the 4 weeks before this study, unless deemed NCS by the Clinical Investigator or Sub-investigator.
  • Any history or evidence of psychiatric or psychological disease, unless deemed NCS by the Clinical Investigator or Sub-investigator.
  • Any history of asthma (after 12 years of age).
  • Any history of severe allergic reaction (including drugs, food, insect bites, environmental allergens).
  • Known history or presence of food allergies, or any condition known to interfere with the absorption, distribution, metabolism or excretion of drugs.
  • Any history of drug and psychoactive medicines abuse.
  • Any recent history of alcohol abuse (less than 1 year).
  • Use of any prescription medication within 14 days preceding this study.
  • Use of vaccinations within 30 days preceding this study.
  • Use of over-the-counter (OTC) medication within the 7 days preceding this study (except for spermicidal/barrier contraceptive products, sunscreen and sunblock products).
  • Participation as a plasma donor in a plasmapheresis program within 7 days preceding this study.
  • Blood donations within 60 days preceding and after this study.
  • Participation in a clinical trial with an investigational drug within 180 days preceding this study, and agreement not to participate in a clinical trial for 180 days after this study.
  • Intolerance to venipuncture.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02132897


Locations
Layout table for location information
Uruguay
Center for Clinical Pharmacology Research Bdbeq S.A. Italian Hospital
Montevideo, Uruguay, 11800
Sponsors and Collaborators
Center for Clinical Pharmacology Research Bdbeq S.A.
Investigators
Layout table for investigator information
Study Director: Francisco E. Estevez-Carrizo, M.D. Center for Clinical Pharmacology Research Bdbeq S.A.
Principal Investigator: Francisco T. Estevez-Parrillo, M.D. Center for Clinical Pharmacology Research Bdbeq S.A.

Layout table for additonal information
Responsible Party: Francisco E. Estevez-Carrizo, M.D., Chief Medical Officer, Center for Clinical Pharmacology Research Bdbeq S.A.
ClinicalTrials.gov Identifier: NCT02132897     History of Changes
Other Study ID Numbers: BDBEQ-CBZ400/EUFUY-023
First Posted: May 7, 2014    Key Record Dates
Last Update Posted: June 17, 2014
Last Verified: June 2014

Keywords provided by Francisco E. Estevez-Carrizo, M.D., Center for Clinical Pharmacology Research Bdbeq S.A.:
Antiepileptic
Carbamazepine
Bio-equivalence
Fed
Crossover

Additional relevant MeSH terms:
Layout table for MeSH terms
Carbamazepine
Anticonvulsants
Antimanic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Psychotropic Drugs
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Sodium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Cytochrome P-450 CYP3A Inducers
Cytochrome P-450 Enzyme Inducers